Literature DB >> 7436494

Brucellosis treated with rifampicin.

J Llorens-Terol, R M Busquets.   

Abstract

14 children, aged between 15 months and 14 years, with brucellosis were treated with oral rifampicin only (20 mg/kg per day) for 3 weeks. Laboratory diagnosis depended on blood culture (positive for Brucella melitensis in 11 of the cases), serum agglutination, complement-fixation test, and Coomb's test. Response was good in each child, with fever clearing between the 2nd and 8th day. 2 children relapsed, but one relapse was probably a reinfection from contaminated cheese. Both children were given a further course of treatment (rifampicin and co-trimoxazole) which was successful. Despite the reasonably good results with rifampicin alone, it is advisable to combine the drug with co-trimoxazole when treating brucellosis.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7436494      PMCID: PMC1626938          DOI: 10.1136/adc.55.6.486

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  5 in total

1.  Trimethoprim-sulfamethoxazole in brucellosis.

Authors:  G K Daikos; N Papapolyzos; N Marketos; S Mochlas; S Kastanakis; E Papasteriadis
Journal:  J Infect Dis       Date:  1973-11       Impact factor: 5.226

2.  Brucellosis.

Authors:  E Williams
Journal:  Br Med J       Date:  1973-03-31

3.  [Health aspects of human brucellosis in Spain].

Authors:  M Mezquita Lopez
Journal:  Rev Sanid Hig Publica (Madr)       Date:  1971-04

4.  The significance of brucella antibodies in patients in a rural area.

Authors:  J D Coghlan; H J Longmore
Journal:  Practitioner       Date:  1973-11

5.  Infection at the subcellular level. II. Distribution and fate of intravenously injected brucellae within phagocytic cells of guinea pigs.

Authors:  H Guerra; R L Deter; R P Williams
Journal:  Infect Immun       Date:  1973-11       Impact factor: 3.441

  5 in total
  11 in total

1.  Possible implications of doxycycline-rifampin interaction for treatment of brucellosis.

Authors:  J D Colmenero; L C Fernández-Gallardo; J A Agúndez; J Sedeño; J Benítez; E Valverde
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

2.  Multicenter prospective study of treatment of Brucella melitensis brucellosis with doxycycline for 6 weeks plus streptomycin for 2 weeks.

Authors:  J M Cisneros; P Viciana; J Colmenero; J Pachón; C Martinez; A Alarcón
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

Review 3.  Neurobrucellosis.

Authors:  R A Shakir
Journal:  Postgrad Med J       Date:  1986-12       Impact factor: 2.401

Review 4.  Brucella endocarditis.

Authors:  M O Jeroudi; M A Halim; E J Harder; M B Al-Siba'i; G Ziady; E N Mercer
Journal:  Br Heart J       Date:  1987-09

Review 5.  Recognition and optimum treatment of brucellosis.

Authors:  J Solera; E Martínez-Alfaro; A Espinosa
Journal:  Drugs       Date:  1997-02       Impact factor: 9.546

6.  In vitro activities of new macrolides and rifapentine against Brucella spp.

Authors:  J A García-Rodríguez; J L Muñoz Bellido; M J Fresnadillo; I Trujillano
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

7.  Quinolones in treatment of human brucellosis: comparative trial of ofloxacin-rifampin versus doxycycline-rifampin.

Authors:  M Akova; O Uzun; H E Akalin; M Hayran; S Unal; D Gür
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

Review 8.  Use of rifampin in nonstaphylococcal, nonmycobacterial disease.

Authors:  A B Morris; R B Brown; M Sands
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

9.  Doxycycline-rifampin versus doxycycline-streptomycin in treatment of human brucellosis due to Brucella melitensis. The GECMEI Group. Grupo de Estudio de Castilla-la Mancha de Enfermedades Infecciosas.

Authors:  J Solera; M Rodríguez-Zapata; P Geijo; J Largo; J Paulino; L Sáez; E Martínez-Alfaro; L Sánchez; M A Sepulveda; M D Ruiz-Ribó
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

10.  Comparative trial of rifampin-doxycycline versus tetracycline-streptomycin in the therapy of human brucellosis.

Authors:  J Ariza; F Gudiol; R Pallarés; G Rufí; P Fernández-Viladrich
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.